You just read:

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

News provided by

Eli Lilly and Company

Mar 04, 2017, 08:20 EST